Decision Resources, Inc., July 2009, Pages: 27
Numbers tell the story in psychiatric disease drugdevelopment: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth
Business Insights, Jan 2007, Pages: 224
underlying disease promise to transform the treatment of psychiatric and neurological diseases, however research and development of these drugs requires an innovative approach to ensure investment is maximized
Life Science Intelligence, Inc., Jan 2011
- Synthetic polymer for osteoarthritis therapy
- Medical imaging technologies for clinical and pre-clinical applications
- Transcutaneous yet needleless drug delivery system for the injection of drugs
GlobalData, June 2010, Pages: 55
analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes dopamine agonists, adenosine receptor antagonists
La Merie, Nov 2008, Pages: 201
new treatment modalities under preclinical and clinical evaluation. More than 160 companies are involved in diabetes drugdevelopment activities.
The present report provides an extensive competitor
GlobalData, Oct 2011, Pages: 95
Expiries is Expected to be Fulfilled by the Launch of Pipeline Molecules
GlobalData’s research indicates that the market for depression therapeutics is well served by the current approved drugclasses
GlobalData, June 2011, Pages: 55
.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes
Life Science Intelligence, Inc., Dec 2011, Pages: 605
perceptual impairment (MPI), an early indicator of mild cognitive impairment
- Device for dry powder pulmonary delivery to treat patients with Parkinson's disease
- Developing healthier drugs from whole
Axis Research Mind, Nov 2011, Pages: 730
market is expected to reach US$2.8 billion. Our analysisindicates that human and veterinary uses would worth US$2.6 billion and US$2.8 billion, respectively by 2015. Pharmaceuticals account for the largest share
Global Markets Direct, Nov 2011, Pages: 74
pipeline.
- Assess the growth potential of Alkermes, Inc. in its therapy areas of focus.
- Identify newdrug targets and therapeutic classes in the Alkermes, Inc.’s R&D portfolio and develop key strategic
Frost & Sullivan, June 2006
, growth in the market is strongly led by the performance of serotonin-norepinephrine reuptake inhibitors (SNRIs), a class of drugs that features limited generic competition and recently introduced brands
Axis Research Mind, Nov 2011, Pages: 730
market is expected to reach US$2.8 billion. Our analysisindicates that human and veterinary uses would worth US$2.6 billion and US$2.8 billion, respectively by 2015.
Among the technologies used, biomarkers accounts
Axis Research Mind, Nov 2011, Pages: 771
market is expected to reach US$2.8 billion. Our analysisindicates that human and veterinary uses would worth US$2.6 billion and US$2.8 billion, respectively by 2015. Private Banks are forecasted to be the fastest
Axis Research Mind, Nov 2011, Pages: 656
$2.8 billion.
Our analysisindicates that human and veterinary uses would worth US$2.6 billion and US$2.8 billion, respectively by 2015.
Report Focus:
The ‘Biobanking: Applications - A Global
GBI Research, May 2011, Pages: 164
provides an in-depth analysis of the top five lifestyle disorders therapeutic indications, which are erectile dysfunction, obesity, alopecia, smoking cessation and alcohol dependence. Furthermore, it also
Global Markets Direct, Nov 2011, Pages: 81
the growth potential of Cortex Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify newdrug targets and therapeutic classes in the Cortex Pharmaceuticals, Inc.’s R&D portfolio and develop key
